BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:21 PM
 | 
Apr 09, 2010
 |  BC Extra  |  Company News

FDA wants additional Pixuvri trial

FDA issued a complete response letter for an NDA from Cell Therapeutics Inc. (NASDAQ:CTIC; Milan:CTIC) for Pixuvri pixantrone to treat relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). The...

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >